Search AI Products and News

Alibaba's AI model, DAMO PANDA, has recently received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This achievement marks a significant breakthrough in early pancreatic cancer screening, offering new possibilities for early diagnosis. DAMO PANDA, developed by Alibaba's DAMO Academy, is an AI model focused on pancreatic cancer screening. Its primary function is to analyze plain CT images and accurately identify subtle lesions that are difficult for the human eye to detect.

Alibaba's AI model, DAMO PANDA, has been officially designated a breakthrough medical device by the U.S. Food and Drug Administration (FDA). This certification marks a significant breakthrough for Alibaba in the field of AI-powered healthcare and represents the first time a leading Chinese tech company has received this prestigious recognition. DAMO PANDA, developed by Alibaba's DAMO Academy, is an AI model designed for pancreatic cancer screening. It aims to accurately identify subtle lesions in CT images, aiding in early detection of the disease.

A medical team at Ningbo University Affiliated People's Hospital recently used artificial intelligence to successfully detect early-stage pancreatic cancer in a seemingly routine case. 65-year-old Mr. Qiu visited the hospital due to dizziness for three consecutive days. While routine examinations revealed no abnormalities, the AI system, through in-depth analysis of his imaging data, issued a timely alert indicating a potential risk of pancreatic cancer. This case utilized a "Plain CT Scan + AI" approach, a cutting-edge technology that...